| Name | follicle stimulating hormone (protein family or complex) |
|---|---|
| Synonyms | Follicle stimulating hormone; Follitropin; Follitropins |
| Name | DMPA |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 16895950 | Matthiesson KL, McLachlan RI, O'Donnell L, Frydenberg M, Robertson DM, Stanton PG, Meachem SJ: The relative roles of follicle-stimulating hormone and luteinizing hormone in maintaining spermatogonial maturation and spermiation in normal men. J Clin Endocrinol Metab. 2006 Oct;91(10):3962-9. Epub 2006 Aug 8. INTERVENTIONS: Subjects (n = 6/group) were assigned to 6 wk of 1) (T) implant (4 x 200 mg sc once)+depot medroxy (DMPA; 150 mg im once); 2) T implant+DMPA+FSH (300 IU sc twice weekly); and 3) T implant+DMPA+human chorionic gonadotropin (hCG; 1000 IU sc twice weekly as an LH substitute). |
1(0,0,0,1) | Details |
| 15722065 | Beksinska ME, Smit JA, Kleinschmidt I, Farley TM, Mbatha F: Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone or combined oral contraceptives for contraception. Contraception. 2005 Mar;71(3):170-5. Follicle-stimulating hormone (FSH) level > or=25.8 mIU/mL was associated with a decrease of 0.017 g/cm2 in radius BMD relative to women with FSH <25.8 mIU/mL. Most studies show that depot-medroxyprogesterone acetate (DMPA) has a negative effect on bone mass. |
1(0,0,0,1) | Details |
| 12316139 | Abdel-sayed WS, Toppozada HK, Said SA, El-sayed OK: Some metabolic and hormonal changes in women using long acting injectable contraceptives. Alex J Pharm Sci. 1989 Mar;3(1):29-32. Statistically significant suppression of the estimated hormones, Follitropin, Luteotropin, and Estradiol-17beta were detected in both groups of NET/EN and DMPA users, after 6 and 12 months, as compared with the preinjection values. |
31(0,1,1,1) | Details |
| 14636937 | Beksinska ME, Smit JA, Kleinschmidt I, Rees HV, Farley TM, Guidozzi F: Detection of raised FSH levels among older women using depomedroxyprogesterone and norethisterone Contraception. 2003 Nov;68(5):339-43. The objective of this study was to investigate whether follicle-stimulating hormone (FSH) levels can be used reliably to indicate approaching menopause in older (aged 40-49), long-term users of depomedroxyprogesterone (DMPA) and norethisterone (NET-EN). |
6(0,0,1,1) | Details |
| 17900438 | Juliato CT, Fernandes A, Marchi NM, Castro S, Olivotti B, Bahamondes L: Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age. Contraception. 2007 Oct;76(4):282-6. Epub 2007 Aug 9. OBJECTIVE: To assess the usefulness of follicle-stimulating hormone (FSH) measurements for determining menopause in 40-55-year-old users of depot medroxyprogesterone acetate (DMPA). |
6(0,0,1,1) | Details |
| 15639696 | Toh YC, Jain J, Rahnny MH, Bode FR, Ross D: Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Clin Ther. 2004 Nov;26(11):1845-54. BACKGROUND: A new -only, nondaily depot medroxyprogesterone acetate (DMPA) SC injectable contraceptive suspension (104 mg/0.65 mL) has been developed. Serum concentrations of MPA, luteinizing hormone, and follicle-stimulating hormone were measured during the 91-day dosing interval and for an additional 15 days thereafter. |
1(0,0,0,1) | Details |
| 6234145 | Lan PT, Aedo AR, Landgren BM, Johannisson E, Diczfalusy E: Return of ovulation following a single injection of depo- a pharmacokinetic and pharmacodynamic study. Contraception. 1984 Jan;29(1):1-18. The effect of a single dose of 150 mg of depo- (DMPA) on pituitary, ovarian and endometrial function was assessed in relation to the peripheral levels of the compound in 8 women. The levels of follitropin (FSH), lutropin (LH), prolactin, (E2) and ( Prog .) were measured 3 times a week during a pretreatment (control) cycle and then daily during postinjection weeks 14-17, 22-25 and 30-33. |
1(0,0,0,1) | Details |
| 3159547 | Friedl KE, Plymate SR, Paulsen CA: Transient reduction in serum HDL- following and testosterone cypionate administration to healthy men. Contraception. 1985 Apr;31(4):409-20. Serum (T), and sex hormone binding globulin (SHBG), luteinizing hormone (LH), and follicle stimulating hormone (FSH) concentrations were all significantly depressed during the drug administration period. Serum lipids were examined in thirty normal male volunteers who had received depo- (DMPA) and testosterone cypionate (TC) in a male contraceptive trial. |
1(0,0,0,1) | Details |
| 8899256 | Virutamasen P, Leepipatpaiboon S, Kriengsinyot R, Vichaidith P, Muia PN, Sekadde-Kigondu CB, Mati JK, Forest MG, Dikkeschei LD, Wolthers BG, d'Arcangues C: Pharmacodynamic effects of depot-medroxyprogesterone acetate (DMPA) administered to lactating women on their male infants. Contraception. 1996 Sep;54(3):153-7. Urinary follicle stimulating hormone (FSH), luteinizing hormone (LH), unconjugated and unconjugated were measured by radioimmunoassay, and serum MPA and urinary MPA metabolites were measured by gas chromatography-mass spectrometry (GC-MS). |
1(0,0,0,1) | Details |
| 8725700 | Mishell DR Jr: Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996 May;41(5 Suppl):381-90. Depot medroxyprogesterone acetate (DMPA) is an aqueous suspension of 17-acetoxy 6-methyl administered by intramuscular injection for long-term contraception. The circulating MPA initially inhibits the midcycle leutinizing hormone (LH) peak, but LH and follicle stimulating hormone (FSH) levels remain in the range of those for the luteal phase of a pretreatment control cycle. |
1(0,0,0,1) | Details |